What is OS Therapies's G&A?

OS Therapies (OSTX) reported G&A of $2.82M in Q1 2026.

How has OS Therapies's G&A changed year-over-year?

OS Therapies's G&A decreased by 23.7% year-over-year, from $3.69M to $2.82M.

What is the long-term trend for OS Therapies's G&A?

Over 2 years (2023 to 2025), OS Therapies's G&A has grown at a 231.6% compound annual growth rate (CAGR), from $1.12M to $12.34M.

Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

OS Therapies OSTX G&A

G&A at other companies

ImmunomeIMNM

$12.95M+21.1%

CTO

Citius Oncology, Inc.CTOR

$23.63M+953%

Avalo TherapeuticsAVTX

$6.85M+23.6%

Arcus BiosciencesRCUS

$29M+3.6%

Segments

By segment

See full

Chief Operating Decision Maker$2.82M-23.7%

Other financials

Income statement

See full

Operating income-$10.2M-103%

Net income-$10.4M-168%

EPS (diluted)-$0.27-50.0%

Balance sheet

See full

Cash & equivalents$917.6K-69.1%

Total debt$20.0M—

Total equity-$10.8M-159%

Total assets$7.3M+71.7%

Cash flow

See full

Operating cash flow-$4.6M-32.6%

CapEx$316.4K—

Free cash flow-$3.7M—

Valuation

See full

Market cap$84.62M+65.5%

Enterprise value$103.7M—

Returns & leverage

See full

Return on equity470%—

Debt / equity-1.8×—

Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is OS Therapies's G&A?: OS Therapies (OSTX) reported G&A of $2.82M in Q1 2026.
How has OS Therapies's G&A changed year-over-year?: OS Therapies's G&A decreased by 23.7% year-over-year, from $3.69M to $2.82M.
What is the long-term trend for OS Therapies's G&A?: Over 2 years (2023 to 2025), OS Therapies's G&A has grown at a 231.6% compound annual growth rate (CAGR), from $1.12M to $12.34M.
What does G&A mean?: Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.